RE:RE:RE:RE:RE:RE:RE:RE:Prothena and Management's ReportingKBC, no milestone has ever been reported reached. At the very least, with all the relationships past and present, Bioasis should at least report on xB3 and whether any relationship "faded" away because of a problem with xB3.
That's not bashing.
About regulators, if there are unreported problems with xB3 and if it is the cause of relationships "fading" away then that is unrevealed material information. Is xB3 good enough to back an IND submission to the FDA? After all these years, NOT ONE IND APPLICATION.
It's simple. Bioasis can give guidance on the capabilities of xB3 and on whether and when it expects an IND submission to be made by anybody. That does not require any secret to be revealed unless there is a secret being withheld that is material and that regulators might consider to be a problem.
And what bombshell might be dropped into an AGM and special meeting agenda?
Shareholders need to know the state of Bioasis and xB3.
For the record, and as you will learn, I have a big interest in Bioasis.
jd